RVTY Stock - Revvity, Inc.
Unlock GoAI Insights for RVTY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.76B | $2.75B | $3.31B | $3.83B | $3.78B |
| Gross Profit | $1.32B | $1.32B | $1.76B | $2.28B | $1.99B |
| Gross Margin | 48.0% | 48.1% | 53.2% | 59.6% | 52.6% |
| Operating Income | $410.52M | $399.49M | $781.12M | $1.34B | $1.02B |
| Net Income | $295.83M | $-118,378,000 | $569.18M | $943.16M | $728.10M |
| Net Margin | 10.7% | -4.3% | 17.2% | 24.6% | 19.2% |
| EPS | $2.41 | $-0.95 | $4.51 | $8.12 | $6.53 |
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 15th 2025 | BofA Securities | Downgrade | Neutral | $110 |
| December 9th 2025 | Goldman | Initiation | Neutral | $105 |
| October 16th 2025 | Guggenheim | Initiation | Neutral | - |
| May 1st 2025 | UBS | Upgrade | Buy | $115 |
| January 10th 2025 | Bernstein | Downgrade | Market Perform | $130 |
| December 13th 2024 | BofA Securities | Upgrade | Buy | $138 |
| October 15th 2024 | Barclays | Upgrade | Overweight | $140← $125 |
| August 28th 2024 | Wells Fargo | Initiation | Equal Weight | $130 |
| July 8th 2024 | Leerink Partners | Initiation | Outperform | $125 |
| June 3rd 2024 | Jefferies | Resumed | Hold | $115 |
| January 16th 2024 | UBS | Downgrade | Neutral | $125← $105 |
| January 4th 2024 | Evercore ISI | Upgrade | Outperform | $125← $88 |
| December 19th 2023 | Wells Fargo | Initiation | Equal Weight | $95 |
| December 13th 2023 | Wolfe Research | Initiation | Peer Perform | - |
| September 28th 2023 | Bernstein | Initiation | Outperform | $133 |
Earnings History & Surprises
RVTYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | — | — | — | — |
Q1 2026 | Jan 30, 2026 | $1.55 | — | — | — |
Q4 2025 | Oct 27, 2025 | $1.14 | $1.18 | +3.5% | ✓ BEAT |
Q3 2025 | Jul 28, 2025 | $1.14 | $1.18 | +3.5% | ✓ BEAT |
Q2 2025 | Apr 28, 2025 | $0.96 | $1.01 | +5.2% | ✓ BEAT |
Q1 2025 | Jan 31, 2025 | $1.37 | $1.42 | +3.6% | ✓ BEAT |
Q4 2024 | Nov 4, 2024 | $1.13 | $1.28 | +13.3% | ✓ BEAT |
Q3 2024 | Jul 29, 2024 | $1.12 | $1.22 | +8.9% | ✓ BEAT |
Q2 2024 | Apr 29, 2024 | $0.94 | $0.98 | +3.9% | ✓ BEAT |
Q1 2024 | Feb 1, 2024 | $1.15 | $1.25 | +8.7% | ✓ BEAT |
Q4 2023 | Oct 30, 2023 | $1.19 | $1.18 | -0.8% | ✗ MISS |
Q3 2023 | Aug 1, 2023 | $1.18 | $1.21 | +2.5% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $1.06 | $1.01 | -4.7% | ✗ MISS |
Q1 2023 | Feb 14, 2023 | $1.66 | $1.70 | +2.4% | ✓ BEAT |
Q4 2022 | Oct 2, 2022 | $1.44 | $0.55 | -61.9% | ✗ MISS |
Q3 2022 | Jul 3, 2022 | $2.01 | $1.42 | -29.4% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $2.12 | $1.40 | -34.0% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $1.50 | — | — |
Q3 2021 | Sep 30, 2021 | $2.25 | $1.11 | -50.7% | ✗ MISS |
Q2 2021 | Jun 30, 2021 | — | $2.19 | — | — |
Latest News
Barclays Maintains Overweight on Revvity, Raises Price Target to $115
📈 PositiveWells Fargo Maintains Equal-Weight on Revvity, Raises Price Target to $107
➖ NeutralGoldman Sachs Initiates Coverage On Revvity with Neutral Rating, Announces Price Target of $105
➖ NeutralKey deals this week: Merck, Day One Biopharmaceutical, ABN AMRO, Revvity, Centerspace and more
➖ NeutralRevvity Agrees To Acquire ACD/Labs, Terms Undisclosed; Transaction Expected To Close Late In Q4 2025
📈 PositiveBarclays Maintains Overweight on Revvity, Raises Price Target to $105
📈 PositiveBaird Maintains Outperform on Revvity, Raises Price Target to $123
📈 PositiveRevvity Board Authorized New $1B Share Repurchase Program
📈 PositiveRevvity Raises FY2025 Adj EPS Guidance from $4.85-$4.95 to $4.90-$5.00 vs $4.86 Est; Widens FY2025 Sales Guidance from $2.840B-$2.880B to $2.830B-$2.880B vs $2.849B Est
➖ NeutralRevvity Q3 Adj. EPS $1.18 Beats $1.14 Estimate, Sales $698.949M Miss $700.457M Estimate
➖ NeutralGuggenheim Initiates Coverage On Revvity with Neutral Rating
➖ NeutralEvercore ISI Group Maintains Outperform on Revvity, Lowers Price Target to $106
➖ NeutralRevvity Expands Type 1 Diabetes Portfolio With Sanofi Support; To Develop T1D 4-Plex IVD Assay Based On Existing RUO 3-Plex Assay
📈 PositiveB of A Securities Maintains Buy on Revvity, Lowers Price Target to $99
📈 PositiveFrequently Asked Questions about RVTY
What is RVTY's current stock price?
What is the analyst price target for RVTY?
What sector is Revvity, Inc. in?
What is RVTY's market cap?
Does RVTY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RVTY for comparison